Astrazeneca

Pharmalot By Ed Silverman

AstraZeneca loses court battle to prevent generic versions of Crestor

Pharmalot By Ed Silverman

To split or not to split? One Wall Street wag thinks Pfizer may remain intact

Pharmalot By Ed Silverman

Sanders, other lawmakers urge FDA approval of generic Crestor

Pharmalot By Ed Silverman

AstraZeneca sues FDA to prevent generic versions of Crestor

Pharmalot By Ed Silverman

Pharmalot, Pharmalittle: Endo may sell assets as reliance on price hikes wanes

Pharmalot By Ed Silverman

Pharmalot, Pharmalittle: AstraZeneca takes $80 million hit on ‘ineffective’ flu vaccine

Business By Leah Samuel

AstraZeneca plans to scour 2 million genomes for rare disease genes

Pharmalot By Ed Silverman

Pharmalot, Pharmalittle: Valeant looks to sign Perrigo chief as its new CEO

Pharmalot By Ed Silverman

Pharmalot, Pharmalittle: Allergan plans ad blitz for its double chin drug

Pharmalot By Ed Silverman

Pharmalot, Pharmalittle: AstraZeneca suffers setback with its blood thinner

Pharmalot By Ed Silverman

Up and down the ladder: The latest comings and goings

Pharmalot By Ed Silverman

Pharmalot, Pharmalittle: AstraZeneca reworks executive pay and revenue goals

Health By Rebecca Robbins

In the shadow of an opioid crisis, Super Bowl ad spotlights chronic pain patients

Pharmalot By Ed Silverman

Maker of generic version of Nexium goes blue to settle litigation

Business By Andrew Joseph

Most Read

The sale of Watson Health assets ends a dark chapter for IBM. For its buyer, the opportunity looks brighter

Up and down the ladder: The latest comings and goings

Once billed as a revolution in medicine, IBM’s Watson Health is sold off in parts

Pharmalittle: Alzheimer’s patient groups to protest Medicare plan for Biogen drug; cancer combo treatments are questioned

What genetic counselors can teach the CDC about communicating uncertainty

It’s staff, not stuff: Applying crisis standards of care to allocating health care workers

For doctors drowning in emails, one health system’s new strategy: pay for replies

If the Biogen CEO were truly ‘courageous,’ he would live with the Medicare decision

All Coverage

AstraZeneca loses court battle to prevent generic versions of Crestor

To split or not to split? One Wall Street wag thinks Pfizer may remain intact

Sanders, other lawmakers urge FDA approval of generic Crestor

AstraZeneca sues FDA to prevent generic versions of Crestor

Pharmalot, Pharmalittle: Endo may sell assets as reliance on price hikes wanes

Pharmalot, Pharmalittle: AstraZeneca takes $80 million hit on ‘ineffective’ flu vaccine

AstraZeneca plans to scour 2 million genomes for rare disease genes

Pharmalot, Pharmalittle: Valeant looks to sign Perrigo chief as its new CEO

Pharmalot, Pharmalittle: Allergan plans ad blitz for its double chin drug

Pharmalot, Pharmalittle: AstraZeneca suffers setback with its blood thinner

Up and down the ladder: The latest comings and goings

Pharmalot, Pharmalittle: AstraZeneca reworks executive pay and revenue goals

In the shadow of an opioid crisis, Super Bowl ad spotlights chronic pain patients

Maker of generic version of Nexium goes blue to settle litigation

Why drug makers share their prized compound libraries with competitors